{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-21-093979","form_type":"8-K","ticker":"NTRA","cik":"0001604821","company_name":"Natera, Inc.","filed_at":"2021-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.818030+00:00","generated_at":"2026-06-30T04:06:53.384212+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Natera reports preliminary Q2 revenue ~$138-141M (+60% YoY); Women's Health cash flow breakeven","bullets":["Total revenue expected $138-141M vs $86.5M in Q2 2020, a record ~60% YoY growth.","Product revenue $135-137M, up ~70% YoY from $80.4M; processed ~370,000 tests (+58%).","Women's Health business achieved cash flow breakeven for the first time in Q2 2021.","Loss from operations widened to $113-117M from $51.7M due to higher R&D and SG&A costs.","On May 11, 2021 entered a development/option deal: paid $10M; option to buy assets for $290M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-21-093979","json":"https://secwatch.observer/filing/0001104659-21-093979.json","markdown":"https://secwatch.observer/filing/0001104659-21-093979.md","text":"https://secwatch.observer/filing/0001104659-21-093979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1604821/000110465921093979/0001104659-21-093979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1604821/000110465921093979/tm2115665d4_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T04:06:53.384212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}